Olympia E. Anastasiou, Marek Widera, Sandra Westhaus, Lejla Timmer, Johannes Korth, Guido Gerken, Ali Canbay, Daniel Todt, Eike Steinmann, Tatjana Schwarz, Jörg Timm, Jens Verheyen, Sandra Ciesek – 19 September 2018 – Acute hepatitis B virus (HBV) infection remains a frequent cause of acute liver failure (ALF) worldwide. ALF occurs in 0.1%‐0.5% of infected patients. The aim of this study was to scrutinize the outcome of patients with HBV‐induced ALF and mutational patterns of HBV variants, which might contribute to ALF.

Charlotte E. Costentin, Yanik J. Bababekov, Andrew X. Zhu, Heidi Yeh – 19 September 2018 – Liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC) because it removes tumor as well as the underlying cirrhotic liver. Because of a global organ shortage, LT for patients with HCC is limited to patients with expected survival comparable to that of nonmalignant indications. Therefore, identifying patients with lower rates of HCC recurrence and higher rates of survival is critical.

Janghyun Kim, Bora Lee, Dae‐Hwan Kim, Jae Gwang Yeon, Jeongkyung Lee, Younjung Park, Yuna Lee, Soo‐Kyung Lee, Seunghee Lee, Jae W. Lee – 19 September 2018 – Regulation of the protein stability of epigenetic regulators remains ill‐defined despite its potential applicability in epigenetic therapies. The histone H3‐lysine 4‐methyltransferase MLL4 is an epigenetic transcriptional coactivator that directs overnutrition‐induced obesity and fatty liver formation, and Mll4+/‐ mice are resistant to both.

Peter Ferenci, Wolfgang Stremmel, Anna Członkowska, Ferenc Szalay, André Viveiros, Albert Friedrich Stättermayer, Radan Bruha, Roderick Houwen, Tudor Lucian Pop, Rudolf Stauber, Michael Gschwantler, Jan Pfeiffenberger, Cihan Yurdaydin, Elmar Aigner, Petra Steindl‐Munda, Hans‐Peter Dienes, Heinz Zoller, Karl Heinz Weiss – 19 September 2018 – Wilson disease (WD) is an inherited disorder of hepatic copper metabolism with considerable variation in clinical presentations, the most common ones being liver disease and neuropsychiatric disturbances.

Douglas B. Mogul, Xun Luo, Jacqueline Garonzik‐Wang, Mary G. Bowring, Allan B. Massie, Kathleen B. Schwarz, Andrew M. Cameron, John F. P. Bridges, Dorry L. Segev – 19 September 2018 – The increased use of split‐liver transplantation (SLT) represents a strategy to increase the supply of organs. Although outcomes after SLT and whole liver transplantation (WLT) are similar on average among pediatric recipients, we hypothesized that the relationship between graft type and outcomes may vary depending on patient, donor, and surgical characteristics.

Britt A. Blokker, Monica Maijo, Marta Echeandia, Mikel Galduroz, Angela M. Patterson, Anna Ten, Mark Philo, Rebecca Schungel, Virginia Gutierrez‐de Juan, Emina Halilbasic, Claudia Fuchs, Gwenaelle Le Gall, Malgorzata Milkiewicz, Piotr Milkiewicz, Jesus M. Banales, Simon M. Rushbrook, José M. Mato, Michael Trauner, Michael Müller, María Luz Martínez‐Chantar, Marta Varela‐Rey, Naiara Beraza – 19 September 2018 – Cholestasis comprises aetiologically heterogeneous conditions characterized by accumulation of bile acids in the liver that actively contribute to liver damage.

Jeannette D. Widmer, Andrea Schlegel, Mohamed Ghazaly, Brian Richie Davidson, Charles Imber, Dinesh Sharma, Massimo Malago, Joerg‐Matthias Pollok – 19 September 2018 – The cava‐preserving piggyback (PB) technique requires only partial cava clamping during the anhepatic phase in liver transplantation (LT) and, therefore, maintains venous return and may hemodynamically stabilize the recipient. Hence, it is an ongoing debate whether PB implantation is more protective from acute kidney injury (AKI) after LT when compared with a classic cava replacement (CR) technique.

Charlotte E. Costentin, Yanik J. Bababekov, Andrew X. Zhu, Heidi Yeh – 19 September 2018 – Liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC) because it removes tumor as well as the underlying cirrhotic liver. Because of a global organ shortage, LT for patients with HCC is limited to patients with expected survival comparable to that of nonmalignant indications. Therefore, identifying patients with lower rates of HCC recurrence and higher rates of survival is critical.

Michael L. Volk, Jessica Mellinger, Meena B. Bansal, Ziad F. Gellad, Mark McClellan, Fasiha Kanwal – 18 September 2018 – Healthcare reimbursement is shifting from fee‐for‐service to fee‐for‐value. Cirrhosis, which costs the U.S. healthcare system as much as heart failure, is a prime target for value‐based care. This article describes models in which physician groups or health systems are paid for improving quality and lowering costs for a given population of patients with cirrhosis.

Kristina I. Ringe, Aristeidis Grigoriadis, Emina Halibasic, Frank Wacker, Michael P. Manns, Christoph Schramm, Henrike Lenzen, on behalf of the MRI working group of the IPSCSG – 17 September 2018